Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Beatriz Mateos
Created: Friday, 14 July 2023, 2:22 PM
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST study
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 5:40 PM
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
Year: 2024
Source: ECCO'24 Stockholm
Authors: Verstockt, Bram
Created: Tuesday, 30 April 2024, 5:03 PM
DOP80: Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s Disease refractory to anti-tumor necrosis factor: A multi-center comparative study
Year: 2020
Source: ECCO'20 Vienna
Authors: Hadrien Alric
Created: Tuesday, 23 June 2020, 5:40 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ololade Lawal
Created: Friday, 14 July 2023, 2:22 PM
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Year: 2024
Source: ECCO'24 Stockholm
Authors: Chaparro, María
Created: Tuesday, 30 April 2024, 5:03 PM
DOP81: Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Sibley, Cailin
Created: Tuesday, 30 April 2024, 5:03 PM
DOP81: Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE Sustain
Year: 2020
Source: ECCO'20 Vienna
Authors: Séverine Vermeire
Created: Tuesday, 23 June 2020, 5:40 PM
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ho-Su Lee
Created: Friday, 14 July 2023, 2:22 PM
DOP82: Biological Treatment Cycles in Crohn’s Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nurulamin Noor
Created: Friday, 14 July 2023, 2:22 PM
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectin
Year: 2020
Source: ECCO'20 Vienna
Authors: Marte Becker
Created: Tuesday, 23 June 2020, 5:40 PM
DOP83: Intestinal epithelium-specific deletion of the Aryl hydrocarbon Receptor (AhR) reduces intestinal Tight Junction permeability thereby hindering homeostatic antigen sampling and tolerogenic immune responses.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Saha, Kushal
Created: Tuesday, 30 April 2024, 5:03 PM
DOP83: Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn’s disease receiving maintenance infliximab: A randomized controlled trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ben Kang
Created: Friday, 14 July 2023, 2:22 PM
DOP84: Colonic CD4+ T cell senescence is implicated in the progression of experimental colitis in aged mice
Year: 2024
Source: ECCO'24 Stockholm
Authors: Zhang, Yang
Created: Tuesday, 30 April 2024, 5:03 PM
DOP84: Crohn’s Disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
Year: 2020
Source: ECCO'20 Vienna
Authors: Carolina Serena
Created: Tuesday, 23 June 2020, 5:40 PM
DOP85: An anti-fibrotic role for eosinophils in a DSS colitis RAG-/- and an in vitro co-culture model
Year: 2024
Source: ECCO'24 Stockholm
Authors: Jacobs, Inge
Created: Tuesday, 30 April 2024, 5:03 PM
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Julien Schulberg
Created: Friday, 14 July 2023, 2:22 PM
DOP86: FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Wellens, Judith
Created: Tuesday, 30 April 2024, 5:03 PM
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jean-Frédéric Colombel
Created: Friday, 14 July 2023, 2:22 PM
DOP87: Characterization of pathologic fibroblast and macrophage cell populations in colonic Crohn’s Disease with spatial transcriptomics.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gudiño, Victoria
Created: Tuesday, 30 April 2024, 5:03 PM